Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke - The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan

被引:370
作者
Ogawa, Akira
Mori, Etsuro
Minematsu, Kazuo
Taki, Waro
Takahashi, Akira
Nemoto, Shigeru
Miyamoto, Susumu
Sasaki, Makoto
Inoue, Takashi [1 ]
机构
[1] Iwate Med Univ, Sch Med, Dept Neurosurg, Morioka, Iwate 0208505, Japan
[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi 980, Japan
[3] Natl Cardiovasc Ctr, Suita, Osaka 565, Japan
[4] Mie Univ, Grad Sch Med, Tsu, Mie 514, Japan
[5] Jichi Med Univ, Sch Med, Shimono, Japan
[6] Kyoto Univ, Grad Sch Med, Kyoto, Japan
关键词
acute; local fibrinolysis; middle cerebral artery; stroke; urokinase; ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN-ACTIVATOR; INTRAVENOUS THROMBOLYSIS; THERAPY; INFARCTION; COMPLICATIONS; PROUROKINASE; ALTEPLASE; OCCLUSION; PROACT;
D O I
10.1161/STROKEAHA.107.488551
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose - The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan was organized to determine the safety and clinical efficacy of intraarterial infusion of urokinase (UK) in patients with stroke within 6 hours of onset. Methods - Patients with ischemic stroke presenting within 6 hours of onset and displaying occlusions of the M1 or M2 portion of the middle cerebral artery on carotid angiography were randomized to the UK or control groups. Clinical outcome was assessed by the modified Rankin Scale, National Institutes of Health Stroke Scale, and Barthel Index. Results - The Independent Monitoring Committee recommended stopping the trial after approval of intravenous infusion of recombinant tissue plasminogen activator in Japan. A total of 114 patients underwent randomization, 57 patients in each group. Background characteristics were comparable between the 2 groups. The primary end point of favorable outcome (modified Rankin Scale 0 to 2) at 90 days was somewhat more frequent in the UK group than in the control group (49.1% and 38.6%, OR: 1.54, 95% CI: 0.73 to 3.23) but did not reach a significant level (P = 0.345). However, excellent functional outcome (modified Rankin Scale 0 to 1) at 90 days, a preplanned secondary end point, was more frequent in the UK group than in the control group (42.1% and 22.8%, P = 0.045, OR: 2.46, 95% CI: 1.09 to 5.54). There were significantly more patients with National Institutes of Health Stroke Scale 0 or 1 at 90 days in the UK group than the control group (P = 0.017). The 90- day cumulative mortality was 5.3% in the UK group and 3.5% in the control group (P = 1.000), and intracerebral hemorrhage within 24 hours of treatment occurred in 9% and 2%, respectively (P = 0.206). Conclusions - The trial was aborted prematurely and the primary end point did not reach statistical significance. Nevertheless, the secondary analyses suggested that intraarterial fibrinolysis has the potential to increase the likelihood of excellent functional outcome.
引用
收藏
页码:2633 / 2639
页数:7
相关论文
共 35 条
[1]   Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study [J].
Albers, Gregory W. ;
Thijs, Vincent N. ;
Wechsle, Lawrence ;
Kemp, Stephanie ;
Schlaug, Gottfried ;
Skalabrin, Elaine ;
Bammer, Roland ;
Kakuda, Wataru ;
Lansberg, Maarten G. ;
Shuaib, Ashfaq ;
Coplin, William ;
Hamilton, Scott ;
Moseley, Michael ;
Marks, Michael P. .
ANNALS OF NEUROLOGY, 2006, 60 (05) :508-517
[2]   ACUTE STROKE INTERVENTION WITH INTRAARTERIAL UROKINASE INFUSION [J].
BARR, JD ;
MATHIS, JM ;
WILDENHAIN, SL ;
WECHSLER, L ;
JUNGREIS, CA ;
HORTON, JA .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1994, 5 (05) :705-713
[3]   Outcome after local intra-arterial fibrinolysis compared with the natural course of patients with a dense middle cerebral artery on early CT [J].
Bendszus, M ;
Urbach, H ;
Ries, F ;
Solymosi, L .
NEURORADIOLOGY, 1998, 40 (01) :54-58
[4]   PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke [J].
del Zoppo, GJ ;
Higashida, RT ;
Furlan, AJ ;
Pessin, MS ;
Rowley, HA ;
Gent, M .
STROKE, 1998, 29 (01) :4-11
[5]   RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR IN ACUTE THROMBOTIC AND EMBOLIC STROKE [J].
DELZOPPO, GJ ;
POECK, K ;
PESSIN, MS ;
WOLPERT, SM ;
FURLAN, AJ ;
FERBERT, A ;
ALBERTS, MJ ;
ZIVIN, JA ;
WECHSLER, L ;
BUSSE, O ;
GREENLEE, R ;
BRASS, L ;
MOHR, JP ;
FELDMANN, E ;
HACKE, W ;
KASE, CS ;
BILLER, J ;
GRESS, D ;
OTIS, SM .
ANNALS OF NEUROLOGY, 1992, 32 (01) :78-86
[6]   LOCAL INTRA-ARTERIAL FIBRINOLYTIC THERAPY IN ACUTE CAROTID TERRITORY STROKE - A PILOT-STUDY [J].
DELZOPPO, GJ ;
FERBERT, A ;
OTIS, S ;
BRUCKMANN, H ;
HACKE, W ;
ZYROFF, J ;
HARKER, LA ;
ZEUMER, H .
STROKE, 1988, 19 (03) :307-313
[7]   THROMBOLYTIC INTERVENTION IN ACUTE THROMBOTIC AND EMBOLIC STROKE [J].
DELZOPPO, GJ ;
PESSIN, MS ;
MORI, E ;
HACKE, W .
SEMINARS IN NEUROLOGY, 1991, 11 (04) :368-384
[8]   SELECTIVE AND SUPERSELECTIVE INFUSION OF UROKINASE FOR EMBOLIC STROKE [J].
EZURA, M ;
KAGAWA, S .
SURGICAL NEUROLOGY, 1992, 38 (05) :353-358
[9]   Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial [J].
Furlan, A ;
Higashida, R ;
Wechsler, L ;
Gent, M ;
Rowley, H ;
Kase, C ;
Pessin, M ;
Ahuja, A ;
Callahan, F ;
Clark, WM ;
Silver, F ;
Rivera, F .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2003-2011
[10]   Dose escalation of desmoteplase for acute ischemic stroke (DEDAS) - Evidence of safety and efficacy 3 to 9 hours after stroke onset [J].
Furlan, AJ ;
Eyding, D ;
Albers, GW ;
Al-Rawi, Y ;
Lees, KR ;
Rowley, HA ;
Sachara, C ;
Soehngen, M ;
Warach, S ;
Hacke, W .
STROKE, 2006, 37 (05) :1227-1231